Carbapenems: Difference between revisions
(Created page with "* Imipenem (+ cilastatin), meropenem ** Cephalosporin-resistant nosocomial bacteria ** Empirical treatment of serious infections in patients who recently received other b-lact...") |
No edit summary |
||
| Line 1: | Line 1: | ||
==Types== | |||
#[[Ertapenem]] | |||
#[[Doripenem]] | |||
#[[Imipenem]] | |||
#[[Meropenem]] | |||
==Indications== | |||
* Cephalosporin-resistant nosocomial bacteria | |||
* Empirical treatment of serious infections in patients who recently received other b-lactams | |||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
| Line 7: | Line 13: | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
*[[Beta Lactams]] | |||
*[[Cephalosporin Cross-reactivity]] | |||
==Source== | ==Source== | ||
Revision as of 02:51, 29 December 2014
Types
Indications
- Cephalosporin-resistant nosocomial bacteria
- Empirical treatment of serious infections in patients who recently received other b-lactams
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
See Also
Source
Goodman & Gilman's Pharmacology